FDA DEVICE FACTS
FIBERGRAFT Aeridyan Matrix Bone Graft Substitute
Prosidyan, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
FIBERGRAFT® Aeridyan
™ Matrix - Bone Graft Substitute is indicated only for bony voids or gaps th a t are not intrinsic to the stability of the bony structure.
FIBERGRAFT® Aeridyan
™ Matrix is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., the postero
lateral spine , extremities and pelvis ). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process. FIBERGRAFT® Aeridyan
™ Matrix must be used with autogenous bone marrow aspirate and autograft in posterolateral spine
. FIBERGRAFT® Aeridyan™ Matrix must be hydrated with saline or blood for pelvis and extremity applications.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。